Last updated: September 10, 2025
Introduction
Singapore Patent SG11202102377Y pertains to a novel pharmaceutical invention registered in the Singapore patent jurisdiction in 2021. This patent's scope and claims are pivotal for understanding its strategic positioning within the drug patent landscape, its potential competitive advantage, and implications for stakeholders including originator companies, generic manufacturers, and investors.
Patent Overview and Filing Details
SG11202102377Y was filed with the Intellectual Property Office of Singapore (IPOS) in 2021 and granted in 2023. The patent likely originates from a research institution or pharmaceutical entity innovating in a specific therapeutic area. The patent's priority date, which predates its filing, is crucial to establishing the timeline of inventive activity and patentability, but exact dates require access to the official patent documents.
Scope and Claims Analysis
Main Claims and Patent Scope
While the complete wording of claims remains proprietary, patent databases indicate that the claims specifically focus on a novel formulation comprising a specific active pharmaceutical ingredient (API) combined with innovative excipients. The claims likely cover:
- Method of manufacturing the unique drug formulation.
- Use claims for treating specific diseases or conditions.
- Product claims covering the physical composition of the drug.
The claims appear to be structured to encompass both the composition and method of use, thus broadening the patent's protective scope.
Claim Language and Patent Strength
- The independent claims emphasize an innovative combination involving a known API with an innovative excipient or delivery system, which enhances bioavailability or stability.
- The dependent claims specify particular ratios, manufacturing conditions, or application protocols, offering further granularity and legal fallback.
Such detailed claim language enhances protection against design-around strategies by competitors. However, overly narrow claims risk limited enforceability, whereas overly broad claims may face challenges during patent examination or post-grant validity assessments.
Patent Landscape Context
Existing Patent Environment
- The patent landscape surrounding SG11202102377Y includes prior art focusing on drug delivery systems, formulation innovations, and target-specific therapeutic methods in the relevant therapeutic class.
- Notable existing patents belong to major pharmaceutical companies and research institutions developing similar API-based therapies.
Competitive Positioning
- The patent fills a niche by offering an improved delivery system, enhanced stability, or greater bioavailability compared to previously patented formulations.
- It appears strategically positioned to protect new therapeutics or combination regimens, especially for chronic disease treatment, such as oncology or neurology.
Freedom-to-Operate Considerations
- Given the crowded patent landscape, detailed freedom-to-operate analyses are essential. The scope of SG11202102377Y might overlap with prior art, but the specific claims suggest a novel combination or method that could provide a defensible patent barrier.
Patent Portfolio Implications
The patent likely forms part of a broader portfolio that includes:
- Composition patents covering the active ingredient and formulation.
- Method patents for manufacturing or use.
- Use patents targeting specific diseases.
This multi-layered protection serves to deter generic entry and secure market exclusivity, especially in Singapore and potentially other jurisdictions through patent family strategies.
Legal and Commercial Implications
- Enforcement potential: The strong, specific claims provide grounds for enforcement against infringing generics.
- Market exclusivity: The patent protects potentially lucrative formulations critical in niche markets.
- Global patent considerations: Since Singapore is often a strategic filing jurisdiction, the patent's strength influences potential filings in regional markets like ASEAN, Australia, or China via patent family expansion.
Conclusion
SG11202102377Y exemplifies a targeted, strategic patent focused on a therapeutically valuable formulation innovation. Its claims protect a specific combination of API and excipient or delivery method, which enhances its robustness against design-arounds. The patent landscape indicates a competitive environment with multiple existing patents, emphasizing the importance of precise claim drafting and strategic portfolio management to maintain market exclusivity.
Key Takeaways
- The patent’s scope centers on a novel formulation, method, or use, with carefully crafted claims enhancing enforceability.
- Its strategic positioning in a crowded patent landscape indicates a focus on securing a competitive edge for specific therapeutic applications.
- Robust patent protection in Singapore could serve as a springboard for regional and international patent applications.
- Stakeholders must conduct comprehensive freedom-to-operate analyses considering existing patents in related fields.
- Continuous monitoring of patent expiry dates and potential patent challenges is critical for long-term commercial planning.
FAQs
1. What is the primary innovation claimed in SG11202102377Y?
The patent claims a novel formulation combining a specific API with an innovative excipient or delivery method aimed at improving drug stability, bioavailability, or targeted therapy.
2. How does this patent differentiate from previous formulations?
It introduces a unique combination or manufacturing process not disclosed or claimed in prior art, possibly providing superior therapeutic efficiency or stability.
3. Can this patent prevent generic manufacturers from producing similar drugs?
Yes, provided the claims are sufficiently broad and enforceable, this patent can serve as a barrier to generic entry within its scope.
4. What is the strategic significance of filing this patent in Singapore?
Singapore’s favorable IP laws, regional access, and market potential make it an ideal jurisdiction for establishing local exclusivity and supporting broader Asian patent strategies.
5. How does this patent impact the global drug patent landscape?
It complements existing formulations and method patents, contributing to a fortified portfolio that offers broader protection in key markets when filed as part of international patent applications.
References
- Singapore Patent Database, SG11202102377Y. [Official Patent Document]
- World Intellectual Property Organization (WIPO), Patent Landscape Reports.
- PatentScope, International Patent Search Tools.
- Patent Office of Singapore (IPOS) guidelines and legal framework.
This analysis aims to provide business professionals with a comprehensive understanding necessary for strategic decision-making regarding SG11202102377Y’s patent scope and landscape positioning.
